August 4, 2025
RESPINOR Secures CE Mark for RESPINOR DXT Under EU MDR – Enabling European Market Launch Read more
November 22, 2024
The FDA has designated RESPINOR DXT as a Breakthrough Device Read more
July 16, 2024
Operator independent continuous ultrasound monitoring of diaphragm excursion predicts successful weaning from mechanical ventilation: a prospective observational study, Demoule et al. Critical Care (2024) 28:245. Read more
July 21, 2023
RESPINOR announces new Chair of the Board Read more
December 9, 2022
First patient included in the multicenter, multinational DE-RISK WF II study in Europe Read more
January 4, 2022
RESPINOR is strengthening the team preparing for commercialization of DXT Read more
October 15, 2021
RESPINOR AS Successfully completed Private Placement of approx. NOK 20 million (€ 2,0 million) Read more
June 18, 2021
RESPINOR has started the last phase of the clinical program, DE-RISK-WF study in Europe, with DXT before regulatory submission (EU and USA) Read more
April 22, 2021
Interview: The winners of the NLSInvest Rising Star Award Read more
April 20, 2021
RESPINOR Announced Winner at the Nordic Life Science Investment Days Read more
March 23, 2021
Kitron and RESPINOR in MedTech partnership Read more
December 11, 2020
RESPINOR awarded 14.2M NOKs from the Research Council of Norway Read more
May 4, 2020
RESPINOR winner of the European Innovation Councils (EIC) ePitching event for COVID-19 solutions Read more
March 6, 2020
RESPINOR made Deloitte’s Technology Fast 50 list Read more
June 21, 2019
RESPINOR featured in Kapital magazine – Norway’s biggest financial magazine Read more
April 17, 2019
First patient enrolled in RESPINOR’s mechanical ventilation WEAN-US study at Hospitalier Pitié-Salpêtrière in Paris, France. Read more
March 26, 2019
First patient enrolled in RESPINOR’s weaning study at St.Olav’s hospital in Trondheim, Norway. Read more
March 8, 2019
RESPINOR at EIC investor’s day at Nasdaq Stockholm Read more
December 12, 2018
DNB Nordic Healthcare Conference 2018, Oslo, Norway Read more
December 4, 2018
RESPINOR DXT tested with principal investigator prior to study commencing in Paris, France Read more
October 15, 2018
RESPINOR part of Norwegian Business Delegation to Beijing, China Read more
September 5, 2018
Market introduction for Norwegian Health Tech Companies to Minneapolis, US Read more
June 25, 2018
RESPINOR AS obtained ISO 13485:2016 certification Read more
April 20, 2018
3.2 million patients are using respirator every year – Norwegian invention makes the costly treatment less expensive Read more
January 31, 2018
Respinor AS has passed Stage 1 of the ISO certification process after no non-conformities were found. The next and final audit is scheduled for May 2018. Read more
October 28, 2017
Test of novel device to measure respiratory function presented at international conference in Milan Read more
February 7, 2017
Respinor ranked number one of a total of 237 in Europe Read more
Cookie Consent by Free Privacy Policy Generator
Update cookies preferences
